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Abstract
Background: Complete diagnosis and therapy of seasonal allergic rhinoconjunctivitis require evidence that exposure to the
sensitizing pollen triggers allergic symptoms. Electronic clinical diaries, by recording disease severity scores and pollen exposure,
can demonstrate this association. However, patients who spontaneously download an e-diary app show very low adherence to
their recording.
Objective: The objective of our study was to assess adherence of patients with seasonal allergic rhinitis to symptom recording
via e-diary explicitly prescribed by an allergist within a blended care approach.
Methods: The @IT-2020 project is investigating the diagnostic synergy of mobile health and molecular allergology in patients
with seasonal allergic rhinitis. In the pilot phase of the study, we recruited Italian children (Rome, Italy) and adults (Pordenone,
Italy) with seasonal allergic rhinitis and instructed them to record their symptoms, medication intake, and general conditions daily
through a mobile app (Allergy.Monitor) during the relevant pollen season.
Results: Overall, we recruited 101 Italian children (Rome) and 93 adults (Pordenone) with seasonal allergic rhinitis. Adherence
to device use slowly declined during monitoring in 3 phases: phase A: first week, ≥1267/1358, 90%; phase B: second to sixth
week, 4992/5884, 80% to 90%; and phase C: seventh week onward, 2063/2606, 70% to 80%. At the individual level, the adherence
assessed in the second and third weeks of recording predicted with enough confidence (Rome: Spearman ρ=0.75; P<.001;
Pordenone: ρ=0.81; P<.001) the overall patient adherence to recording and was inversely related to postponed reporting (ρ=–0.55;
P<.001; in both centers). Recording adherence was significantly higher during the peak grass pollen season in Rome, but not in
Pordenone.
Conclusions: Adherence to daily recording in an e-diary, prescribed and motivated by an allergist in a blended care setting,
was very high. This observation supports the use of e-diaries in addition to face-to-face visits for diagnosis and treatment of
seasonal allergic rhinitis and deserves further investigation in real-life contexts.
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Introduction
Background
Seasonal allergic rhinoconjunctivitis (SAR) affects patients
exposed to pollens to which they are sensitized. The etiological
diagnosis and therapy of SAR require a demonstration that
exposure to the sensitizing pollen triggers allergic symptoms
[1]. Objectively, this link is established by a positive outcome
to nasal allergen provocation tests [2] or allergen exposure in
pollen chambers [3]. Unfortunately, both these tests are costly
and time consuming and are mostly used in clinical trials [4].
In clinical daily life, a causality between pollen exposure and
symptoms is often assessed by a careful retrospective clinical
history [5]. However, recall biases make the diagnosis based
on retrospective data somewhat imprecise, especially in patients
apparently sensitized to multiple pollens that share the same
pollination periods [6], which is a frequent setting in
Mediterranean countries [7].
This diagnostic problem can be partially solved through a
prospective clinical history, based on the patient’s daily
recording of symptoms and medication intake in a clinical diary
[8]. Indeed, the trajectories of daily symptom scores or a
combined symptom and medication score (CSMS) are free from
recall bias and can be matched with daily concentration counts,
obtained in parallel, of the potentially eliciting pollen sources
[9,10]. While traditional and time-consuming clinical diaries
on paper records are rarely used, electronic clinical diaries
(e-diaries) have become increasingly prevalent [11,12]. E-diaries
are apps consisting of short questionnaires filled in daily by the
patient, usually on his or her mobile phone or tablet computer
[11-13]. Recording e-diaries is easy and quick, and the software
automatically provides daily scores, time trajectories, and
descriptive reports [8,10-16].
Several e-diaries are available for pollen allergies in European
countries, and some of them have also been used in trials or
observational studies [8,10,12,14-19]. In most of the study
settings, the app was directly downloaded by the patients, with
no or only occasional intervention by their allergist [14-17].
The observational studies were characterized by large population
size (more than 9000 participants) and big datasets (112,054
registered visual analog scale [VAS] data) [14], balanced by a
poor mean adherence (<10%) to daily recording [14,15].
Objective
We hypothesized that the patients’ adherence to recording of
e-diaries would be significantly increased if the rationale and
the use of the e-diary were personally explained by an allergist
to the patient (blended approach). To test this hypothesis, we
examined the rate and cofactors of adherence to recording of
an e-diary among Italian patients with SAR participating in the
@IT-2020 project, a study of combined molecular diagnostics




The pilot study of the @IT-2020 project was carried out in 2
Italian centers differing significantly in terms of environmental
setting and patient characteristics.
Climate and Study Area
Pordenone, Italy, is a city with about 50,000 inhabitants, which
extends over an area of 38 km2 [20]. Pordenone is 600 km north
of Rome and the territory is located in northeastern Italy, about
50 km from the Adriatic Sea, in the Po-Veneto plain south of
the Carnic Pre-Alps, in the continental biogeographical region
[21]. It has a mean annual temperature of 13.1°C and mean
rainfall of 1292 mm [22].
Rome, Italy, has 3 million inhabitants in an area of almost 1300
km2 [20] and is 20 km from the Tyrrhenian Sea. Rome is located
in the Mediterranean biogeographical region [21] with mean
annual temperature of 15.7°C and mean rainfall of 798 mm
(Rome Monte Mario) [22].
Study Population
Between November 2016 and February 2017, we recruited 101
children aged 10 to 18 years at Ospedale Sandro Pertini in Rome
and 93 adults aged over 18 years at Ospedale Santa Maria degli
Angeli in Pordenone. Criteria for eligibility were (1) being
followed up for at least one year for allergic rhinoconjunctivitis
(objectively confirmed by skin prick tests or in vitro
immunoglobulin E tests, or both) due to outdoor aeroallergens
(pollen or spores), (2) residing within 30 km of the
aerobiological station of the study center, (3) having no intention
to change residence in the 6 months after recruitment, and (4)
being able to use a mobile phone (by the patient or the patient’s
parents). Exclusion criteria were (1) previous allergen
immunotherapy for any outdoor allergen, and (2) any other
severe nonatopic chronic disease. All participants (in the case
of children, their parents or guardians) provided informed
written consent to the clinical investigations.
Study Design
Recruited patients underwent a first clinical assessment (T0),
including clinical questionnaires, during which they were
instructed on the use of the Allergy.Monitor (Technology Project
and Software [TPS] Production, Rome, Italy) mobile app to
monitor their symptoms and medication intake during the
following study period. According to the timing of retrospective
symptoms and skin prick test results, participants were assigned
an individual monitoring period during the suspected high
season of the putative eliciting pollen. During this period,
participants were asked to monitor their eye, nose, and lung
symptoms, as well as their effect on daily activities and daily
medication intake, and report them via Allergy.Monitor. After
the monitoring period, all participants underwent a second
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clinical assessment (T1), including a repetition of the initial
clinical questionnaires focused on the past pollen season,
internationally validated by the International Study of Asthma
and Allergies in Childhood [23], the Allergic Rhinitis and its
Impact on Asthma (ARIA) initiative [24,25], and the Global
Initiative for Asthma [26]. The study design and procedures
had been approved by the ethics committee of each participating
center.
Skin Prick Tests
Skin prick tests were performed using a standard panel of
commercial extracts (ALK-Abelló, Milan, Italy) of outdoor and
indoor aeroallergens (Alternaria, Bermuda grass, birch, cat
dander, cypress, dog dander, hazel, house dust mite, mugwort,
olive tree, plane tree, ragweed, Russian thistle, timothy grass,
and pellitory-of-the-wall). Histamine 0.1 mg/mL and glycerol
solution were used as positive and negative controls,
respectively. Morrow Brown needles were used to prick the
skin and the wheal reactions were read after 15 minutes. A wheal
equal to or greater than 3 mm after subtraction of the negative
control was regarded as positive.
Pollen Counts and Pollen Periods
The pollen count data, acquired from March 1 to September 30,
2016, were provided by the pollen stations of Rome (Tor
Vergata University) and Pordenone (Agenzia Regionale per la
Protezione dell’Ambiente del Friuli Venezia Giulia). Pollen
was collected using a VPPS 2000 pollen sampler (Lanzoni srl,
Bologna, Italy), and data were acquired as reported in Standard
UNI CEN/TS 16868:2015 [27]. Pollen periods were determined
(1) according to the 2017 European Academy of Allergy and
Clinical Immunology (EAACI) position paper on pollen
exposure times [28] (EAACI criteria), and (2) by adapting these
criteria to the pollen situation in Italy (local criteria).
Allergy.Monitor
Allergy.Monitor is a mobile app designed for daily reporting
of symptoms and medication intake related to allergic rhinitis
or asthma. In this study, medical doctors, on the basis of clinical
history, defined a time frame (prescription period; Figure 1)
for each patient, in which he or she was encouraged to fill in a
daily questionnaire regarding his or her symptoms and
medication intake. The system offers a bidirectional interaction
between physician and patient via email, chat, and text
messaging. Patients not entering their data for 2 consecutive
days received an automatic alert message on their mobile phone
or by email; after 4 days without reporting, the alert was
followed by a phone call from the physician or nurse. The
patient could insert data referring to 1 day only on the same day
or on the following one (postponed reporting). For each
participant, adherence to prescription was calculated as the
number of actual reporting days / prescription period ×100;
adherence was calculated as the number of actual reporting
days / reporting period ×100; and postponed reporting was
calculated as the number of postponed reporting days / actual
reporting days ×100.
Figure 1. Graphical representation of definitions used in this study. The box line represents the monitored period (each box is a specific day) of a
hypothetical participant. In this example the medical doctor, according to the individual participant’s clinical history, invited the patient to fill in the
e-diary questionnaire for 54 days (prescription period). The patient started to record symptoms 6 days after the prescribed beginning day (delayed
reporting start) and finished recording symptoms 5 days before the prescribed ending day (advanced reporting end). Thus, the reporting period lasted
43 days, during which the participant did not fill in the e-diary questionnaire for 7 days (missing reporting days). Overall, the participant filled in the
e-diary questionnaire for 36 days (reporting days).
Symptom and Medication Scores
We used the following symptom and medication scores in this
study: Rhinoconjunctivitis Total Symptom Score (RTSS; score
0-18) [29]; CSMS (score 0-6) [30]; and VAS (score 0-10) [31].
RTSS and CSMS were calculated automatically by the
Allergy.Monitor app, for every reporting day, on the basis of 4
questions on nasal symptoms (sneezing, rhinorrhea, nasal
pruritus, nasal congestion), 2 on ocular symptoms (itchy eyes,
watery eyes), and 3 questions on medication intake
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(antihistaminic drugs, local corticosteroids, systemic
corticosteroids). The severity of each of the symptoms was also
measured by the patient using 4 different emoticons, each
representing a distinct severity grade (no symptoms, mild,
moderate, or severe). Overall severity was also measured by a
VAS in response to the question “How do you feel in relation
to your allergic symptoms today?”
Statistics
We summarized data as numbers (n) and frequencies (%) if they
were categorical and as mean or median and standard deviation
or interquartile range if quantitative. We examined all described
analyses for each of the study centers (Rome and Pordenone).
We evaluated the prevalence of atopic sensitization (skin prick
test ≥3 mm) to airborne allergens. For every pollen period
considered, we calculated adherence values (see above for
definition) for each participant and compared their means using
a nonparametric Friedman test for repeated measures. We
adjusted the P of multiple comparison by the Bonferroni
correction. We studied adherence trends over time considering
the time (in days) that had passed since the first day of the
reporting period. We used the Spearman rank correlation
coefficient to investigate the relationship between total
adherence (%), postponed reporting (%), and adherence achieved
between the seventh and the 21st reporting day (%). Mean
CSMS scores by time were computed for the local whole season.
We considered P<.05 to be statistically significant. Statistical
analyses were performed with R version 3.2.3 (R Foundation).
Results
Study Population
Overall, 101 children (Rome) and 93 adults (Pordenone) with
mean (SD) ages of 13.7 (SD 2.8) and 34.3 (14.4), respectively,
met the inclusion criteria (Table 1). Male sex was slightly more
frequent in both populations: 62.4% (63/101) for Rome and
56% (52/93) for Pordenone. At T0, according to the ARIA
questionnaire, the population in Pordenone was characterized
by a higher prevalence of moderate to severe (intermittent and
persistent) allergic rhinitis than in Rome (90/93, 97% vs 51/101,
50.5%, respectively). At T1, this difference was less evident
(64/75, 85% vs 68/91, 75%). The prevalence of allergic asthma
was similar in both groups (Rome: 28/101, 27.7%; Pordenone:
24/93, 26%), whereas the Rome population seemed to be more
affected by oral allergy syndrome, urticaria, atopic dermatitis,
and anaphylaxis (Table 1). Grass pollen was the most relevant
allergen in both study populations. Positive skin prick test
reactions to olive tree and cypress were more frequent in Rome,
while sensitization to birch was more prevalent in Pordenone.
Sensitization to indoor allergens was equally prevalent in both
populations.
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Table 1. Characteristics of the study population.
Pordenone (n=93)Rome (n=101)Characteristic
52 (56)63 (62.4)Males, n (%)
34.3 (14)13.7 (2.8)Age (years), mean (SD)
Allergic rhinitis, n (%)
15 (8-22)6 (4-8)Age at onset (years), median (IQRa)
ARIAb classification at T0
1 (1)19 (18.8)Mild intermittent
2 (2)31 (30.7)Mild persistent
17 (18)11 (10.9)Moderate to severe intermittent
73 (79)40 (39.6)Moderate to severe persistent
ARIA classification at T1c, n (%)
2 (3)6 (7)Mild intermittent
9 (12)17 (19)Mild persistent
13 (17)4 (4)Moderate to severe intermittent
51 (68)64 (70)Moderate to severe persistent
Other allergic comorbidities, n (%)
24 (26)28 (27.7)Allergic asthma
23 (25)32 (32.3)Oral allergic syndrome
8 (9)19 (19.2)Urticaria or angioedema
11 (12)28 (28.3)Atopic dermatitis
1 (1)4 (4.0)Gastrointestinal disorders
1 (1)10 (10.1)Anaphylaxis episode
2 (2)5 (5.1)Other
aIQR: interquartile range.
bARIA: Allergic Rhinitis and its Impact on Asthma.
cStudy population at T1: Rome, n=91; Pordenone, n=75.
Pollen Periods
The graphical representation of grass pollen counts (grains/m3)
highlighted differences between the 2 cities. The maximum
grass pollen count in Rome (199 grains/m3) was higher than in
Pordenone (145 grains/m3), and the grass pollination period
was longer in Rome. Grass pollen periods in 2016 differed
significantly if calculated according to EAACI criteria or local
criteria (Table 2). While we used EAACI criteria for their
reproducibility and standardization, the application of locally
adapted criteria resulted in shorter and less fragmented periods.
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Table 2. Grass pollen period criteria and duration, by study center.


















86.3 (83.5-89.2)132282.1 (79.3-84.9)13225 days (out of 7 consecutive days) each
with ≥3 pollen grains/m3 and with a
sum of ≥30 pollen grains/m3
EAACI whole sea-
sonb
86.2 (83.1-89.2)72281.9 (79.1-84.8)9715 days (out of 7 consecutive days) each
with ≥10 pollen grains/m3 and with a
sum of ≥100 pollen grains/m3
Local whole sea-
sonc




90.3 (87.6-92.9)24281.0 (78.0-84.1)5513 days (out of 5 consecutive days) each
with ≥50 pollen grains/m3
Local peak seasonc
89.3 (86.4-92.1)23980.9 (77.9-84.0)4518Days with at least 50 pollen grains/m3EAACI high daysb
aSee Figure 1 for specifications of time periods.
bEuropean Academy of Allergy and Clinical Immunology (EAACI) criteria [28].
cAdaptation of EAACI criteria to the local scenario.
Adherence to E-Diary Recording
The mean prescription period was longer in Rome than in
Pordenone (76.2, 95% CI 70.4-82.0 vs 53.9, 95% CI 50.1-57.7
days, respectively). The pattern was similar for the mean
reporting period (Rome: 70.6, 95% CI 64.9-74.4 vs Pordenone:
48.2, 95% CI 44.6-51.7 days) (Figure 2). Mean adherence levels
were 85.7% (SD 13.9) in Pordenone and 82.3% (SD 13.7) in
Rome. The analysis of mean adherence values by reporting day
showed a similar trend for both participating study centers. In
Rome, the adherence trend by reporting day displayed 3 different
phases: phase A, a first phase of 6 days with an adherence 93.1%
(564/606); phase B, a second phase of approximately 40 days,
during which the adherence fluctuated around 83.65%
(2834/3388); and phase C, a final phase of slowly declining
adherence, oscillating around 78.55% (1952/2485). Pordenone’s
adherence trend by reporting day followed the same evolution
for phases A and B. Due to a shorter pollen season and mean
prescribed period, we did not investigate phase C in Pordenone
(Figure 2).
Figure 2. Adherence (%) by reporting day and study center. It is possible to describe three phases (indicated by light background color): the first phase
(A), lasting 6 days, during which adherence fell from 100% to 90%; the second phase (B), lasting approximately 20 days, during which adherence
fluctuated until reaching 88%; and the final phase (C), during which it slowly declined to 80%. RM: Rome; PN, Pordenone.
Interestingly, the total adherence was directly proportional to
the adherence assessed between the seventh and 21st reporting
days (Spearman ρ=0.75; P<.001 and ρ=0.81; P<.001 for Rome
and Pordenone, respectively) (Figure 3) and inversely related,
although with less intensity, to postponed reporting (ρ=–0.55;
P<.001 for both Rome and Pordenone) (Figure 4). In both
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populations, the mean RTSS, evaluating symptoms of the eyes
and nose, showed a parallel trend with the mean VAS scores
assessing the general disease-related impairment. Also, the
CSMS followed a similar trend but with less distinct variance
(Figure 5).
Mean adherence values differed only slightly in Rome during
the different pollen periods (Figure 6, part A). By contrast,
adherence values were significantly higher in Pordenone during
the peak pollen season and the high day (Figure 6, part B).
Figure 3. Correlation between adherence achieved between the seventh and the 21st reporting days and total reporting period adherence, by study
center: (A) Rome (n=101); (B) Pordenone (n=93).
Figure 4. Correlation between postponed reporting (%) and total reporting period adherence (%) by study center: (A) Rome (n=101); (B) Pordenone
(n=93).
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Figure 5. Mean visual analog scale (VAS) score, Rhinoconjunctivitis Total Symptom Score (RTSS), and combined symptom and medication score
(CSMS) by time considering the local whole season of grass pollen in (A) Rome (n=101) and (B) Pordenone (n=93; see Figure 2 and Table 2 for
definitions).
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Figure 6. Mean (95% CI) adherence to recording of the e-diary during the pollen season in children affected by seasonal allergic rhinitis in (A) Rome
and (B) Pordenone. Adherence was calculated for each patient considering the total reporting period and according to whole, peak, and high days of
pollen periods defined by the European Academy of Allergy and Clinical Immunology (EAACI) and local criteria. See Figure 1 and Table 2 for criteria.
"a" indicates that nonparametric Friedman test for repeated measures was applied and only statistically significant P values of multiple comparisons,
adjusted by Bonferroni correction, are highlighted.
Discussion
Principal Findings
In this bicenter study, we investigated the adherence of Italian
patients with SAR to symptom and medication monitoring via
an e-diary prescribed by their doctor in the context of an
observational study. We found that adherence to recording was
(1) very high (>80%) in the first 7 weeks of monitoring, (2)
predicted by the adherence in the first 3 weeks of the monitoring
period, (3) inversely associated with the frequency of delayed
e-diary compilation, and (4) higher during the peak pollen
season.
The trajectories of the mean adherence to recording were highly
similar in both study populations, notwithstanding their
differences in geographical location (northern vs central Italy)
and age (adults vs children). Moreover, we observed only a few
patients with very low adherence to e-diary recording, that is,
failing to register their symptoms during more than 60% of days
within their monitoring period (not shown).
This level of adherence is at great variance from levels published
in previous studies on e-diaries in patients with allergic rhinitis
who had not been specifically instructed and advised by a doctor
to use an app. With this approach, the Mobile Airways Sentinel
Network observational pilot study among 2871 allergic users
from 15 countries reported an adherence to symptom recording
of only 9.5% after 14 days of recording [14]. A follow-up project
among 9122 users from 22 countries showed that only 16.4%
of the users were still recording their symptoms after 14 days
[15].
Digital technologies have been shown to be a very useful tool
for the assessment of real-life data among big patient groups
[14-17]. While the patient-initiated use of an e-diary app may
be very helpful in highly motivated patients looking for
self-management opportunities, it seems that this scenario
applies to only a minority of the users spontaneously
downloading, installing, and using an e-diary app for allergic
rhinitis [14,15]. However, our results showed that in a blended
care approach combining face-to-face visits with internet-based
support technologies, patients are keen and able to correctly use
an e-diary when contacted and instructed to do so by their
allergist. It has to be underlined, though, that our patients were
participating in an observational clinical study and we do not
know whether their high adherence would have been also
maintained in the context of routine clinical practice. This
hypothesis deserves to be tested in a real-life or surveillance
study.
The adherence to e-diary recording of the patients in Rome was
slightly, but significantly, higher during the grass pollen peak
season, when allergic symptoms were also more severe. This
observation may be easily explained by increased awareness
and motivation linked to symptom severity. This outcome should
be taken into account when considering the use of e-diaries
outside the pollen season or in patients with very mild
symptoms. With regard to monitoring scores, we demonstrated
that the overall VAS score reliably reflected the results of the
RTSS and CSMS, which confirms the usefulness of VASs for
digital symptom assessment as previously shown in other studies
[31,32].
Of great relevance is, in our opinion, that the overall adherence
of a patient to e-diary recording over a period of 2 or more
months can already be predicted with enough confidence in the
second and third weeks of monitoring. Patients at risk of poor
adherence could therefore be identified and receive
supplementary information and education, thus facilitating a
higher compliance.
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First, our study population consisted of Italian patients only, so
that our results now require further evaluation in different
cultural contexts. To this end, we are examining the outcomes
of a similar study performed in 7 southern European and
Mediterranean countries. Second, we cannot comment on
possible outcome improvements, as the study did not include
any control group. Third, we limited our monitoring period to
a maximum of 90 days; we do not know whether the patients’
adherence to recording would have remained high enough
beyond this time frame. Fourth, our results and proposal cannot
be applied to SAR patients not using a mobile phone. Fifth, we
did not evaluate potential adverse effects of the use of an e-diary,
such as excessive attention to disease or even facilitation of
anxiety and obsessive disturbances.
Conclusion
Our study showed that adherence to the daily symptom and
medication monitoring via an e-diary was maintained at a high
level up to 2 months by SAR patients properly informed and
educated by their allergist. This outcome underlines the strength
of a blended care approach and needs now to be confirmed in
a real-life clinical allergy setting. Our results contribute to
reinforce positive expectations for a proper use of mHealth
technology in monitoring patients with SAR for diagnostic and
therapeutic purposes.
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